Intelligent Docetaxel Liposomal Injection System for Enhanced Tumor Treatment
Legal Citation
Summary of the Inventive Concept
An integrated system combining docetaxel liposomal injection with AI, IoT, blockchain, and novel materials to revolutionize targeted tumor treatment, monitoring, and supply chain management.
Background and Problem Solved
The original patent disclosed a composition of docetaxel liposomal injection with high drug loading, but it lacked real-time monitoring, personalized treatment planning, and secure supply chain management. The new inventive concept addresses these limitations by integrating distinct technologies to create a more powerful and efficient system.
Detailed Description of the Inventive Concept
The system consists of a docetaxel liposomal injection with high drug loading, an AI-powered tumor detection module for real-time monitoring and personalized treatment planning, an IoT-enabled sensor for quality control and batch release, a blockchain-based supply chain management system for tracking and authenticating batches, and a novel material composition for vials with enhanced stability and reduced leachables. The synergistic combination of these technologies enables targeted tumor treatment, real-time patient monitoring, and adaptive treatment adjustment.
Novelty and Inventive Step
The new claims introduce a synergistic combination of AI, IoT, blockchain, and novel materials with the original docetaxel liposomal injection composition, providing a non-obvious and innovative solution for targeted tumor treatment and supply chain management.
Alternative Embodiments and Variations
Alternative embodiments may include variations in AI algorithms, IoT sensor configurations, blockchain protocols, and novel material compositions. Additionally, the system could be adapted for use with other antineoplastic agents or disease indications.
Potential Commercial Applications and Market
The intelligent docetaxel liposomal injection system has significant commercial potential in the oncology market, particularly in the areas of targeted tumor treatment, personalized medicine, and supply chain management. The system's ability to provide real-time monitoring, adaptive treatment adjustment, and secure supply chain management makes it an attractive solution for pharmaceutical companies, hospitals, and healthcare providers.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K9/127 |
| A | A61 | A61K9/0019 |
| A | A61 | A61K9/1277 |
| A | A61 | A61K31/337 |
| A | A61 | A61K47/24 |
| A | A61 | A61K47/26 |
| A | A61 | A61K47/28 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical Nanotechnology and Drug Delivery Systems, specifically focused on liposomal formulations of antineoplastic agents with emphasis on targeted drug delivery and advanced manufacturing techniques
Person of Ordinary Skill (PHOSITA) Profile
A pharmaceutical scientist or biomedical engineer with expertise in liposomal drug formulation, nanotechnology, advanced materials, and digital health technologies, holding a PhD or equivalent advanced degree with 3-5 years of specialized research experience
Obviousness Rationale
A PHOSITA would recognize that integrating digital technologies like AI, IoT, and blockchain with existing liposomal drug delivery systems represents a predictable and logical extension of current pharmaceutical innovation strategies. The core docetaxel liposomal composition remains substantially unchanged, while the proposed technological integrations provide enhanced monitoring, quality control, and personalized treatment capabilities. These technological additions represent incremental improvements that would be obvious to a skilled practitioner seeking to optimize drug delivery and patient management systems.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,680 |
|---|---|
| Title | Composition of docetaxel liposomal injection with high drug loading |
| Assignee(s) | SHILPA MEDICARE LIMITED |